Akari Therapeutics PLC (NASDAQ:AKTX)‘s stock had its “neutral” rating reissued by stock analysts at Chardan Capital in a research note issued on Friday. They presently have a $2.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $6.00. Chardan Capital’s price objective suggests a potential downside of 27.49% from the company’s current price.
A number of other research firms also recently weighed in on AKTX. William Blair downgraded Akari Therapeutics PLC from an “outperform” rating to a “market perform” rating in a research note on Friday, May 12th. Zacks Investment Research downgraded Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $15.00 price target (down previously from $33.00) on shares of Akari Therapeutics PLC in a research note on Monday, June 26th.
Shares of Akari Therapeutics PLC (NASDAQ:AKTX) opened at 3.4477 on Friday. Akari Therapeutics PLC has a 12 month low of $3.37 and a 12 month high of $22.20. The stock’s 50 day moving average price is $4.51 and its 200-day moving average price is $7.71. The firm’s market capitalization is $40.60 million.
TRADEMARK VIOLATION WARNING: “Akari Therapeutics PLC (NASDAQ:AKTX) Receives “Neutral” Rating from Chardan Capital” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/08/13/akari-therapeutics-plc-nasdaqaktx-receives-neutral-rating-from-chardan-capital.html.
An institutional investor recently raised its position in Akari Therapeutics PLC stock. VHCP Management II LLC increased its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 426,297 shares of the biopharmaceutical company’s stock after buying an additional 56,807 shares during the period. Akari Therapeutics PLC makes up 0.8% of VHCP Management II LLC’s investment portfolio, making the stock its 13th largest position. VHCP Management II LLC owned 3.62% of Akari Therapeutics PLC worth $1,965,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 28.75% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.